Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367

Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cholesterol, LDL
  • Diabetes Mellitus, Type 2*
  • Humans
  • Proprotein Convertase 9*
  • Proprotein Convertases
  • Subtilisins

Substances

  • Cholesterol, LDL
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Subtilisins